Results 111 to 120 of about 11,492 (188)

Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies

Case Reports in Medicine, 2015
Chronic spontaneous urticaria is an itching skin disease characterised by wheals, angioedema, or both present for more than six weeks. Omalizumab is a humanized anti-IgE monoclonal antibody recently approved for treatment of chronic urticaria.
Misbah Nasheela Ghazanfar, Simon Francis Thomsen   +1 more
doaj   +1 more source

Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster, J. M. P. A. van den Reek, E. M. G. J. de Jong, S. van Beugen, A. I. M. van Laarhoven, I. Haeck, M. de Bruin‐Weller, M. L. Schuttelaar, B. Horvath, A. Gostyński, A. Knulst, M. H. Vermeer, L. Nguyen, L. Gerbens, P. Spuls, M. A. Middelkamp‐Hup, V. Exadaktylos, T. Niemeyer‐van der Kolk, A. R. Schrader, A. M. Sluijmers, J. Versteeg, B. W. M. Arents, I. van Ee, J. L. A. G. van der Zon, M. de Leeuw, T. de Leeuw, P. van den Broek, C. Berkhof, D. Vellinga, S. Weidinger, S. Dubrac, Y. Li, M. van Steensel, M. Marchetti‐Deschmann, M. Maurer, H. van der Zee, J. Damman, D. J. Hijnen, F. Wijk, M. M. B. Seyger, H. Röckmann, D. M. W. Balak, M. B. A. van Doorn, R. Rissmann, The Next Generation ImmunoDermatology (NGID) consortium, Rob Vreeken, Eva Cuypers, Boudewijn Lelieveldt, Abdoel El Ghalbzouri, Hanna Niehues, Ellen van den Bogaard, Tom Ederveen, Els van der Pool, Nanda Olde, Debra Trampe, Ellen Stijl‐’t Hart, Lisanne Wezendonk, Johan Westerhuis, Huma Shehwana, Joerg Schreiber, Jeremy Bost, Mie Bech Lukassen, Jimmy Bakker, Juliette Simons, Fauve van den Berge, Colin Spence, Elise Beljaards, Anastasiia Myronenko, Mariona Oliver   +68 more
wiley   +1 more source

Perceived Acquired Resistance to Omalizumab in Obese Patients With Chronic Spontaneous Urticaria

Clinical &Experimental Allergy, EarlyView.
Francisco Martins, Ilaria Trave, Sofia Pereira, Margarida Gonçalo   +3 more
wiley   +1 more source

Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review assessed 52 biomarkers predicting systemic therapy response and adverse events in atopic dermatitis. Most studies focused on dupilumab, and findings were inconsistent. IgE and eosinophils were largely non‐predictive, though elevated eosinophils and LDH sometimes indicated poorer outcomes.
Eva Hilger, Kaitlyn Chan, Alphonsus Yip, Xingyue Maria Wang, Conor Broderick, Bernd Arents, Karin van Bart, Kilian Eyerich, Joseph Rastrick, Stephan Weidinger, Carsten Flohr, on behalf of the BIOMAP Consortium   +11 more
wiley   +1 more source

Omalizumab for Pediatric Cutaneous Mastocytosis: Case Report and Review

Pediatric Dermatology, EarlyView.
ABSTRACT We report an 11‐month‐old boy with diffuse cutaneous mastocytosis whose severe pruritus and steroid dependence resolved following off‐label treatment with omalizumab. A literature review identified five additional pediatric cases in which omalizumab led to complete symptom resolution in an average of 2 months and permitted discontinuation of ...
Janis Chang, Aliyah King, Adam Byrne, Carmen Liy‐Wong   +3 more
wiley   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

International Journal of Dermatology, Volume 65, Issue 4, Page 706-723, April 2026.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska, Isha Gandhi, Robert Adler, Deena Fayyad, Perya Bhagchandani, Shabnam Afzal, Waleed Adawi, Shivani Patel, Shawn G. Kwatra   +8 more
wiley   +1 more source

Bullous Wells’ syndrome successfully treated with omalizumab

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Giulia Ciccarese, William Andrew Rosato, Francesco Drago, Alexandre Raphael Meduri, Francesca Ambrogio, Aurora De Marco, Gerardo Cazzato, Caterina Foti   +7 more
wiley   +1 more source

Label‐Free Detection of PSA Using Laser‐Induced Graphene/ZnO Nanorod‐Based Impedimetric Immunosensors

Advanced Sensor Research, Volume 5, Issue 3, March 2026.
A label‐free impedimetric immunosensor based on laser‐induced graphene decorated with ZnO nanorods is developed for prostate‐specific antigen detection. Antibody adsorption on ZnO enables clinically relevant sensitivity and an unconventional “signaling‐off” response, where charge‐transfer resistance decreases upon antigen binding, challenging ...
Maria S. Soares, Sónia O. Pereira, António J. S. Fernandes, Florinda M. Costa, Nuno F. Santos   +4 more
wiley   +1 more source

Medicaid Coverage and Utilization for Novel Therapies for Chronic Rhinosinusitis With Nasal Polyposis

International Forum of Allergy &Rhinology, Volume 16, Issue 3, Page 301-304, March 2026.
Key Points Most state Medicaid programs granted omalizumab (91.4%) and dupilumab (59.5%) preferred drug status. Omalizumab was the most commonly prescribed therapy among Medicaid patients between 2015 and2024.
Eric R. Ramos, Sriram Satyavolu, Ashley L. Miller, George A. Scangas, Zachary M. Soler, Rodney J. Schlosser, Yufan Lin, Vinay K. Rathi   +7 more
wiley   +1 more source

Aseptic meningitis due to intravenous immunoglobulin therapy (IVIG) in therapy‐refractory pyoderma gangraenosum

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Katharina A. Kälber, Knut Schäkel, Alexander Enk, Julia K. Winkler   +3 more
wiley   +1 more source